Peptide Library

In clinical trials

Digestive & weight

Petrelintide

Evidence

Clinical trials

Class

Long-acting amylin analog

/

Petrelintide

KEY TAKEAWAY

Petrelintide is a long-acting amylin analog being developed by Zealand Pharma and Roche for weight management. Petrelintide is not FDA-approved and is being tested in clinical trials.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Long-acting amylin analog

Being studied for

Studied for obesity

Key fact

Petrelintide is not FDA-approved and is being tested in clinical trials.

Route

Weekly subcutaneous injection in trials

Evidence strength

Clinical trials

What it is

What it is

Petrelintide is a long-acting amylin analog being developed by Zealand Pharma and Roche for weight management.

How it works

How it works

It acts on amylin receptors to increase fullness. Its developers hope it will cause less nausea than GLP-1 drugs.

Regulatory status

Regulatory status

Petrelintide is not FDA-approved and is being tested in clinical trials.

What it is used for

What it is used for

Studied for obesity.

Side effects and risks

Side effects and risks

Early trials reported mainly mild gut-related effects, but data are limited.

Citations

Citations

Petrelintide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo